Chronic Pain
Conditions
Brief summary
The primary objective of the study is the descriptive analysis of incidence & severity of side effects & reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Buprenorphine patches.
Detailed description
750 patients that are treated with transdermal Buprenorphine patches for chronic pain will be included in the study. About 20% of patients are aimed to be patch-naive, ie have received their first prescription of transdermal analgesic patches within 1 month before inclusion in this observational study. Furthermore the study should not include more than 25% of cancer patients that are treated for chronic pain in order to ensure an appropriate mix of patient population.
Interventions
None listed
Sponsors
Mundipharma Research Limited
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient age \> 18 * Patient is treated with transdermal Buprenorphine * The patient is able to answer the patient's survey & has an estimated overall survival of minimum 6 months * The patient gives his/her informed, written consent to participate in the study
Exclusion criteria
* Patient Age \< 18 * Patient has less than 6 months survival expectancy * Patient is unable to answer the patient survey for whatever reason in any feasible form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence and severity of side effects | patients observed for 6 months | Descriptive analysis of incidence and severity of side effects and reasons for discontinuation with Buprenorphine patches. Safety Issue - No |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment patterns | patients observed for 6 months | Insight into patient profiles treatment patterns and satisfaction. |
Countries
United Kingdom
Outcome results
None listed